Compare Illumina, Inc. (ILMN) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs ServiceNow Inc — how do they compare? Illumina, Inc. trades at $266.99 (market cap $39.95B), while ServiceNow Inc trades at $140.3 (market cap $144.48B). The key difference: ServiceNow Inc is far larger — about 3.6× Illumina, Inc.'s market cap, and Illumina, Inc. is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and ServiceNow Inc for 54 Days on average.
| ILMN | NOW | |
|---|---|---|
Market Cap | $39.95B | $144.48B |
Volume | 3,169,503 | 11,801,699 |
Sector | Health | Technology |
52-Week High | $293.69 | $189.26 |
52-Week Low | $91.00 | $83.00 |
Typical Hold Time | 83 Days | 54 Days |
Enterprise Value | $41.31B | $148.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% on the day but remains near its 52-week high. The stock exhibits a bullish technical trend with strong moving average signals, while recent earnings beats and a significant return to profitability in 2025 highlight fundamental improvement. Positive sentiment is fueled by S&P 500 inclusion and analyst upgrades, though high valuation ratios present a risk.
The outlook is cautiously optimistic, driven by sequencing growth and AI initiatives, but investors face risks from elevated valuations, competitive pressures, and potential margin volatility. The consensus price target of $241 suggests near-term downside from current levels despite a majority of analysts maintaining a Buy rating.
ServiceNow (NOW) trades at $139.75, up 1.29% with bullish technical momentum and strong institutional support. The company demonstrates robust revenue growth from $7.2B in 2022 to $13.3B in 2025, with consistent earnings beats and expanding AI capabilities driving investor optimism. Despite premium valuation metrics (P/E 86.17, P/S 9.75), the stock benefits from positive analyst sentiment with 87% buy ratings and a $146.04 consensus target.
NOW presents a compelling growth story with AI revenue surpassing $1B and projected to triple by 2029. However, elevated valuation multiples and competitive pressures from Atlassian and Palantir warrant caution. The stock's upside depends on sustained AI adoption and margin preservation amid increasing investment requirements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
